“a nonsignificant trend”

Dose escalation to > 63 Gy (maximum 66.6 Gy) to the primary tumor in 38/87 patients revealed a nonsignificant trend for improved 3‐year CFS (82.4% vs. 97%, P = 0.092), a significantly improved CFS for T2/T3 tumors (72.6% vs. 100%, P = 0.008), and a significantly improved 3‐year PFS for T1/T2 tumors (76.7% vs. 100%, P = 0.035).

19.7 years in other households; p = 0.003) with a nonsignificant trend toward males (64.9% vs. 50.2%; p = 0.092).

There was a nonsignificant trend for slightly faster procedural times in patients with meniscus sign (median time 33 min vs. 40 min, p = 0.092).

There was a nonsignificant trend for an interaction between device and mapping procedure, F (1, 87) = 2.91, p = .092, which is likely due to a larger benefit of place-based mapping for the CI-alone simulations than the EAS simulations.

Placental weight did not differ significantly by dose (β = +12.01, 95% CI = −20.50-44.53, P = .469), and the main effect of sex indicated only a nonsignificant trend toward heavier placentas in males (β = +16.12, 95% CI = −2.63-34.86, P = .092).

In Kaplan–Meier analysis, the interaction between PVC count and appropriate ICD shock showed a nonsignificant trend ( p = .093, Figure 2c ). 3.5.

Mean H O showed a nonsignificant trend toward differences between disease categories (one-way anova : F 2,8 = 3.24; P = 0.093; Fig. 2C ), whereas mean allelic richness was significantly different between disease categories (one-way anova : F 2,8 = 7.88; P = 0.013).

Kaplan–Meier estimates suggested a nonsignificant trend toward higher recurrence in ChC versus ICM (56.1% versus 43.4%; p = 0.093), with no differences between ChC and idiopathic DCM (56.1% versus 52.1%; p = 0.434) or between ICM and idiopathic DCM (43.4% versus 52.1%; p = 0.535; Fig. 4 A).

Post hoc comparisons revealed a significant reduction (43%) in mGluR5 binding in the hippocampus of AD ( BP ND = 0.76 ± 0.41) compared to CN ( BP ND = 1.34 ± 0.58, p = 0.003, unpaired t test) participants, and a nonsignificant trend for a reduction in a composite association cortical region in AD ( BP ND = 1.57 ± 0.25) compared to CN ( BP ND = 1.86 ± 0.63, p = 0.093) participants.

An additional model including an interaction term between ICU status and malignancy showed a nonsignificant trend ( p = 0.093), but malignancy alone remained non‐significant ( p = 0.20).

A priori t -tests showed that the CB group had a nonsignificant trend toward reducing target error compared to the SHAM group [ t (17) = 1.78, p = 0.093, d = 0.81, g = 0.78].

21.9%; p=1.000), although a nonsignificant trend toward higher progression was observed at 24 months (25% vs. 11.1%; p=0.093) and five (30% vs. 12.5%; p=0.088).

There was a nonsignificant trend towards increased OS in the erlotinib treatment arm in the Asian subpopulation (HR 0.67, P =0.0931), which reached statistical significance in Asian patients with EGFR IHC- positive status (HR 0.53, P =0.0233).

3 B ), with a nonsignificant trend ( F (2,62) = 2.4618, p = 0.0936, η 2 p = 0.0735) revealed in the one-way ANOVA.

−1.43%, p = 0.025), with a nonsignificant trend of resolution of hepatic steatosis (44.9% vs. 28.6%, p = 0.094) ( 124 ).

NIR significantly enhanced fusion relative to both the control ( p = 0.014) and LED ( p = 0.047), while LED treatment alone showed only a nonsignificant trend toward improvement compared with the control ( p = 0.094).

Compared with bevacizumab, aflibercept extended final treatment intervals by 2.14 weeks ( p < 0.001) and reduced the total number of injections by 2.35 ( p = 0.001), while ranibizumab showed a nonsignificant trend toward longer final intervals (+0.84 weeks; p = 0.094) and did not significantly reduce injection count (−0.51; p = 0.299).

There was a nonsignificant trend toward reduced fatigue according to the FSS in group 1 [median (IQR): 44.0 (31.0–51.0)] than in group 2 [median (IQR): 53.0 (41.3–55.0); P = 0.094] (Fig. 3 ).

28.37 ± 2.53 mm, p = 0.043), whereas L5 anterior height showed only a nonsignificant trend toward a higher value in the anabolic group (29.12 ± 1.97 vs. 28.24 ± 3.80 mm, p = 0.094).

CD103 levels also showed a nonsignificant trend toward lower gene expression in the complete response group compared with the incomplete response group ( P = .094).

While there was a nonsignificant trend toward increased iNOS‐positive proinflammatory macrophages at 2‐day postclosure ( p = 0.0940) and Arginase‐1‐positive proresolution macrophages at 7‐day postclosure ( p = 0.1672) (Figure 7b,c ), we observed an enhancement of Arginase‐1 response (proresolution macrophages) at 7‐day postclosure versus 2 days with LASE ( p = 0.0207) which did not reach significance for sutures ( p = 0.2693).

A nonsignificant trend was observed toward increased Z-score with testosterone treatment duration with a mean increase of 0.07 per year (95% CI, −0.01 to 0.16; P = .094) in men with CHH ( Fig. 2C ).

Median HITS decreased from 3.5 to 0 in the ASA group ( p = 0.012) but showed a nonsignificant trend in controls (4.0 to 0.5, p = 0.095).

In multivariable analysis, while controlling for demographic variables and risky alcohol use, a 5-unit increase in overall SS again showed a nonsignificant trend toward decreased odds of higher risk of an ED ( P =0.095).

There was a nonsignificant trend for an enrichment in basal‐like tumor subtype (RNA signature) in POSTN‐high tumors (POSTN expression assessed by IHC, p = 0.095 or POSTN‐RNAsign , p = 0.056) (supplementary material, Figure S2B,C ).